Fumihiro Ishida

Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study

Motoko Yamaguchi, Yok‐Lam Kwong, Won Seog Kim et al. · Journal of Clinical Oncology · 2011 · 602 citations

Pharmacy, Oncology, Pharmacotherapy +13

A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis

Seok Jin Kim, Dok Hyun Yoon, Arnaud Jaccard et al. · The Lancet Oncology · 2016 · 386 citations · Full text

Medicine, Clinical Sciences, Oncology +15

Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients

Rika Kihara, Yasunobu Nagata, Hitoshi Kiyoi et al. · Leukemia · 2014 · 233 citations · Full text

Life Sciences, Genetics, Oncology +17

Age-related Epstein-Barr virus (EBV)–associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients

Naoko Asano, Kazuhito Yamamoto, Jun‐ichi Tamaru et al. · Blood · 2008 · 161 citations

Medicine, Hematology, Immunology +8

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 159 citations · Full text

Medicine, Immunology, Oncology +13